A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
- PMID: 21757117
- PMCID: PMC3175766
- DOI: 10.1016/j.jacc.2011.03.031
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
Abstract
Objectives: The purpose of this study was to develop a risk stratification score to predict warfarin-associated hemorrhage.
Background: Optimal decision making regarding warfarin use for atrial fibrillation requires estimation of hemorrhage risk.
Methods: We followed up 9,186 patients with atrial fibrillation contributing 32,888 person-years of follow-up on warfarin, obtaining data from clinical databases and validating hemorrhage events using medical record review. We used Cox regression models to develop a hemorrhage risk stratification score, selecting candidate variables using bootstrapping approaches. The final model was internally validated by split-sample testing and compared with 6 published hemorrhage risk schemes.
Results: We observed 461 first major hemorrhages during follow-up (1.4% annually). Five independent variables were included in the final model and weighted by regression coefficients: anemia (3 points), severe renal disease (e.g., glomerular filtration rate <30 ml/min or dialysis-dependent, 3 points), age ≥75 years (2 points), prior bleeding (1 point), and hypertension (1 point). Major hemorrhage rates ranged from 0.4% (0 points) to 17.3% per year (10 points). Collapsed into a 3-category risk score, major hemorrhage rates were 0.8% for low risk (0 to 3 points), 2.6% for intermediate risk (4 points), and 5.8% for high risk (5 to 10 points). The c-index for the continuous risk score was 0.74 and 0.69 for the 3-category score, higher than in the other risk schemes. There was net reclassification improvement versus all 6 comparators (from 27% to 56%).
Conclusions: A simple 5-variable risk score was effective in quantifying the risk of warfarin-associated hemorrhage in a large community-based cohort of patients with atrial fibrillation.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Comment in
-
Anticoagulation therapy: New score for hemorrhage risk.Nat Rev Cardiol. 2011 Aug 2;8(9):481. doi: 10.1038/nrcardio.2011.117. Nat Rev Cardiol. 2011. PMID: 21808272 No abstract available.
-
ACP Journal Club. A 5-item score predicted risk for warfarin-associated major hemorrhage in patients with atrial fibrillation.Ann Intern Med. 2011 Nov 15;155(10):JC5-13. doi: 10.7326/0003-4819-155-10-201111150-02013. Ann Intern Med. 2011. PMID: 22084360 No abstract available.
-
[A new risk scheme to predict warfarin-associated hemorrhage risk in anticoagulation with warfarin].Praxis (Bern 1994). 2011 Nov 30;100(24):1503-4. doi: 10.1024/1661-8157/a000739. Praxis (Bern 1994). 2011. PMID: 22124963 German. No abstract available.
-
The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use.J Am Coll Cardiol. 2012 Jan 10;59(2):194-5; author reply 195. doi: 10.1016/j.jacc.2011.08.071. J Am Coll Cardiol. 2012. PMID: 22222085 No abstract available.
Similar articles
-
Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.J Am Coll Cardiol. 2012 Aug 28;60(9):861-7. doi: 10.1016/j.jacc.2012.06.019. Epub 2012 Aug 1. J Am Coll Cardiol. 2012. PMID: 22858389
-
Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.Am J Med. 2016 Jun;129(6):600-7. doi: 10.1016/j.amjmed.2015.10.001. Epub 2015 Oct 22. Am J Med. 2016. PMID: 26482233
-
Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.Chest. 2013 Jan;143(1):179-184. doi: 10.1378/chest.12-0608. Chest. 2013. PMID: 22722228
-
How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?Am J Cardiol. 2016 Sep 1;118(5):697-9. doi: 10.1016/j.amjcard.2016.06.014. Epub 2016 Jun 15. Am J Cardiol. 2016. PMID: 27394408 Free PMC article.
-
Prevention of stroke in patients with atrial fibrillation.Semin Vasc Med. 2005 Aug;5(3):285-92. doi: 10.1055/s-2005-916168. Semin Vasc Med. 2005. PMID: 16123916 Review.
Cited by
-
Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study.Kidney Dis (Basel). 2024 Aug 16;10(5):346-358. doi: 10.1159/000540107. eCollection 2024 Oct. Kidney Dis (Basel). 2024. PMID: 39430289 Free PMC article.
-
Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants.Clin Kidney J. 2024 Jul 5;17(8):sfae206. doi: 10.1093/ckj/sfae206. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39421237 Free PMC article.
-
Development and Validation of a Predictive Model for Intracranial Haemorrhage in Patients on Direct Oral Anticoagulants.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241271338. doi: 10.1177/10760296241271338. Clin Appl Thromb Hemost. 2024. PMID: 39140863 Free PMC article.
-
Bleeding recurrence risk among hospitalized patients undergoing therapeutic plasma exchange: a multi-center study.Blood Transfus. 2024 Sep;22(5):420-428. doi: 10.2450/BloodTransfus.722. Epub 2024 Jul 19. Blood Transfus. 2024. PMID: 39133623 Free PMC article.
-
National Trends for Temporary Mechanical Circulatory Support Utilization in Patients With Cardiogenic Shock From Decompensated Chronic Heart Failure: Incidence, Predictors, Outcomes, and Cost.J Soc Cardiovasc Angiogr Interv. 2023 Dec 4;2(6Part B):101177. doi: 10.1016/j.jscai.2023.101177. eCollection 2023 Nov-Dec. J Soc Cardiovasc Angiogr Interv. 2023. PMID: 39131060 Free PMC article.
References
-
- Hart R, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine. 2007;146:857–867. - PubMed
-
- Bungard TJ, Ghali WA, McAlister FA, et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Canadian Journal of Cardiology. 2003;19:280–284. - PubMed
-
- Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Annals of Internal Medicine. 1999;131:927–934. - PubMed
-
- Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685–2692. - PubMed
-
- Beyth R, Quinn L, Landefeld C. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–99. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
